Insmed (INSM) Cash from Operations Growth (1y) (2011 - 2026)

Insmed (INSM) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - 60.84%
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 85.14%
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -15.72%
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 74.39%
9 Abivax 91.71 Bn 91.71 Bn - -
10 Insmed 19.79 Bn 18.57 Bn 258.54 Mn 15.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 15.01%
Dec 31, 2025 -26.34%
Sep 30, 2025 -21.47%
Jun 30, 2025 -67.19%
Mar 31, 2025 -42.41%
Dec 31, 2024 -49.81%
Sep 30, 2024 -32.70%
Jun 30, 2024 -0.13%
Mar 31, 2024 -25.79%
Dec 31, 2023 -26.83%
Sep 30, 2023 -51.77%
Jun 30, 2023 -20.03%
Mar 31, 2023 -39.12%
Dec 31, 2022 -22.60%
Sep 30, 2022 -19.06%
Jun 30, 2022 -35.60%
Mar 31, 2022 18.02%
Dec 31, 2021 -25.96%
Sep 30, 2021 -28.60%
Jun 30, 2021 -109.84%